학술논문
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Document Type
Article
Author
Gaur, A.H.; Capparelli, E.V.; Best, B.M.; Calabrese, K.; Baltrusaitis, K.; Marzinke, M.A.; Agwu, A.L.; McCoig, C.; Van Solingen-Ristea, R.M.; Crauwels, H.; Vandermeulen, K.; Mathiba, S.R.; Adeyeye, A.; Townley, E.; Moye, J.H.; Heckman, B.; Kneebone, J.L.; Lowenthal, E.D.; Ward, S.; Milligan, R.; Samson, P.; Harrington, C.M.; Ford, S.L.; Huang, J.; Smith-Anderson, C.; Camacho-Gonzalez, A.; Ounchanum, P.; Bolton Moore, C.; Buisson, S.; Cheung, S.Y.A.; Chounta, V.; Deprez, I.; Desmond, A.C.; Han, K.; Hanley, S.; Lin, Y.-W.; Patel, F.; Paul, M.E.; Roberts, G.; Whitson, K.; Zabih, S.
Source
In: The Lancet HIV . (The Lancet HIV, April 2024, 11(4):e211-e221)
Subject
Language
English
ISSN
23523018